Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update - PubMed (original) (raw)
Practice Guideline
. 2018 Jul 10;36(20):2105-2122.
doi: 10.1200/JCO.2018.77.8738. Epub 2018 May 30.
M Elizabeth Hale Hammond 1, Kimberly H Allison 1, Brittany E Harvey 1, Pamela B Mangu 1, John M S Bartlett 1, Michael Bilous 1, Ian O Ellis 1, Patrick Fitzgibbons 1, Wedad Hanna 1, Robert B Jenkins 1, Michael F Press 1, Patricia A Spears 1, Gail H Vance 1, Giuseppe Viale 1, Lisa M McShane 1, Mitchell Dowsett 1
Affiliations
- PMID: 29846122
- DOI: 10.1200/JCO.2018.77.8738
Free article
Practice Guideline
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C Wolff et al. J Clin Oncol. 2018.
Free article
Abstract
Purpose To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. Recommendations Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in > 10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not "must") be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended work-up for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 ( HER2/chromosome enumeration probe 17 [CEP17] ratio ≥ 2.0; average HER2 copy number < 4.0 signals per cell), ISH group 3 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 6.0 signals per cell), and ISH group 4 ( HER2/CEP17 ratio < 2.0; average HER2 copy number ≥ 4.0 and < 6.0 signals per cell). The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISH and IHC assays. The Expert Panel recommends that laboratories using single-probe ISH assays include concomitant IHC review as part of the interpretation of all single-probe ISH assay results. Find additional information at www.asco.org/breast-cancer-guidelines .
Comment in
- In Reply.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M. Wolff AC, et al. Arch Pathol Lab Med. 2019 Apr;143(4):413-414. doi: 10.5858/arpa.2018-0906-LE. Epub 2019 Jan 3. Arch Pathol Lab Med. 2019. PMID: 30605367 No abstract available. - Human Epidermal Growth Factor Receptor 2 Testing by Fluorescent In Situ Hybridization: Positive or Negative? American Society of Clinical Oncology/College of American Pathologists Guidelines 2007, 2013, and 2018.
Murray C, D'Arcy C, Gullo G, Flanagan L, Quinn CM. Murray C, et al. Arch Pathol Lab Med. 2019 Apr;143(4):412-413. doi: 10.5858/arpa.2018-0905-LE. Epub 2019 Jan 3. Arch Pathol Lab Med. 2019. PMID: 30605368 No abstract available. - Implementation of the 2018 Human Epidermal Growth Factor Receptor 2 Guideline by American Society of Clinical Oncology/College of American Pathologists Will Reduce False-Positive Tests.
Martin V, Valera A, De Joffrey M, Banfi S, Mazzucchelli L. Martin V, et al. Arch Pathol Lab Med. 2019 Apr;143(4):411-412. doi: 10.5858/arpa.2018-0904-LE. Epub 2019 Jan 3. Arch Pathol Lab Med. 2019. PMID: 30605369 No abstract available. - Author's Reply: To the Letter to the Editor by Sorscher.
Allison KH. Allison KH. J Natl Compr Canc Netw. 2021 Jun 30;19(6):xxiii. doi: 10.6004/jnccn.2021.7060. J Natl Compr Canc Netw. 2021. PMID: 34214970 No abstract available. - Clinical Consequences of Altering the Definition of HER2-Positive Breast Cancer to Exclude Group 2, HER2-Negative Disease.
Sorscher S. Sorscher S. J Natl Compr Canc Netw. 2021 Jun 30;19(6):xxii. doi: 10.6004/jnccn.2021.7053. J Natl Compr Canc Netw. 2021. PMID: 34214971 No abstract available.
Similar articles
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Wolff AC, et al. Arch Pathol Lab Med. 2018 Nov;142(11):1364-1382. doi: 10.5858/arpa.2018-0902-SA. Epub 2018 May 30. Arch Pathol Lab Med. 2018. PMID: 29846104 - Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Wolff AC, et al. J Clin Oncol. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Epub 2013 Oct 7. J Clin Oncol. 2013. PMID: 24101045 - UK recommendations for HER2 assessment in breast cancer: an update.
Rakha EA, Tan PH, Quinn C, Provenzano E, Shaaban AM, Deb R, Callagy G, Starczynski J, Lee AHS, Ellis IO 1, Pinder SE. Rakha EA, et al. J Clin Pathol. 2023 Apr;76(4):217-227. doi: 10.1136/jcp-2022-208632. Epub 2022 Dec 23. J Clin Pathol. 2023. PMID: 36564170 Review. - HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.
Ahn S, Woo JW, Lee K, Park SY. Ahn S, et al. J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
Cited by
- Association of Granulocyte Colony-Stimulating Factor Treatment with Risk of Brain Metastasis in Advanced Stage Breast Cancer.
Tai YS, Leung JH, Wang SY, Leung HWC, Chan ALF. Tai YS, et al. Int J Mol Sci. 2024 Oct 6;25(19):10756. doi: 10.3390/ijms251910756. Int J Mol Sci. 2024. PMID: 39409083 Free PMC article. - Improved Prognosis in HER2-Low Breast Cancer Patients with Reduced Ki67 Index After Neoadjuvant Chemotherapy: A Multi-Center Retrospective Study.
Huang M, Jin Y, Wang M, Song Q, Fan Y, Zhang Y, Tian C, Zhang C, Liu S. Huang M, et al. Breast Cancer (Dove Med Press). 2024 Oct 10;16:667-678. doi: 10.2147/BCTT.S478110. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 39403364 Free PMC article. - Machine learning radiomics based on intra and peri tumor PA/US images distinguish between luminal and non-luminal tumors in breast cancers.
Mo S, Luo H, Wang M, Li G, Kong Y, Tian H, Wu H, Tang S, Pan Y, Wang Y, Xu J, Huang Z, Dong F. Mo S, et al. Photoacoustics. 2024 Sep 23;40:100653. doi: 10.1016/j.pacs.2024.100653. eCollection 2024 Dec. Photoacoustics. 2024. PMID: 39399393 Free PMC article. - Whole tumour- and subregion-based radiomics of contrast-enhanced mammography in differentiating HER2 expression status of invasive breast cancers: A double-centre pilot study.
Wang S, Wang T, Guo S, Zhu S, Chen R, Zheng J, Jiang T, Li R, Li J, Li J, Shen X, Qian M, Yang M, Yu S, You C, Gu Y. Wang S, et al. Br J Cancer. 2024 Oct 9. doi: 10.1038/s41416-024-02871-9. Online ahead of print. Br J Cancer. 2024. PMID: 39379571 - Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer.
Zhao Y, Chen X, Wang Y, Zhang X, Ye Y, Xu S, Zhou L, Lin Y, Lu J, Yin W. Zhao Y, et al. Ann Med. 2024 Dec;56(1):2409343. doi: 10.1080/07853890.2024.2409343. Epub 2024 Oct 7. Ann Med. 2024. PMID: 39376056 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous